secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055622
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q1 revenue $66M (+63% YoY); net income $11M; FDA Fast Track for MNKD-101
--------------------------------------------------------------------------------

- Total revenues $66.3M (+63% YoY); GAAP net income $11M; non-GAAP net income $15M.
- Tyvaso DPI royalties surged 94% to $22.7M; collaborations & services revenue up 118% to $24.8M.
- Afrezza net revenue $14.4M (+16%); V-Go down 16% to $4.3M.
- Cash and investments $304.5M; repaid ~$37M of secured debt in early April.
- FDA Fast Track and IND clearance for MNKD-101 (clofazimine inhaled suspension).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000095017024055622/0000950170-24-055622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000095017024055622/mnkd-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer